Search company, investor...


Founded Year



Series C | Alive

Total Raised


Last Raised

$6M | 11 yrs ago

About MicroPhage

MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.

Headquarters Location

2400 Trade Centre Avenue

Longmont, Colorado, 80503,

United States

Missing: MicroPhage's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MicroPhage's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

MicroPhage Patents

MicroPhage has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Bacteriophages, Molecular biology, Microbiology, Genetics, Myoviridae


Application Date


Grant Date



Related Topics

Bacteriophages, Molecular biology, Microbiology, Genetics, Myoviridae



Latest MicroPhage News

Cardinal Health invests in MRSA testing company

Oct 11, 2011

Share / Oct 11, 2011 at 3:07 PM Cardinal Health ( NYSE:CAH ) has secured exclusive North American marketing rights for a recently cleared staph-infection blood test from diagnostics company MicroPhage . In exchange, Dublin, Ohio-based Cardinal has provided MicroPhage with an unspecified amount of operational funding for development and commercialization of new products, according to a statement from MicroPhage. Reached by phone, MicroPhage officials declined to specify the amount of Cardinal’s investment. “Most of it was an equity investment,” said CEO Don Mooney. Colorado-based MicroPhage markets the test as the first test for Staphylococcus aureus infections that is able to quickly identify whether the bacteria are methicillin resistant ( MRSA ) or methicillin susceptible (MSSA). S. aureus is the most common cause of staph infections and can lead to serious conditions like pneumonia and meningitis. Advertisement MRSA infections are resistant to antibiotics and often are found in people who have spent time in hospitals or other healthcare settings. The blood test is capable of delivering results in five-and-a-half hours, compared with current methods that can take up to 72 hours, according to the company. The test was cleared for marketing by the (pdf) U.S. Food and Drug Administration in May. The test “not only saves time in diagnosing potentially life-threatening infections but also allows healthcare professionals to optimize treatment and start appropriate contact precautions to prevent the spread of the organism,” said Alberto Gutierrez of the FDA’s Center for Devices and Radiological Health, at the time. As part of the deal, Cardinal also gets distribution rights to other MicroPhage products in development for testing blood culture specimens for S. aureus, according to the statement. Topics

MicroPhage Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MicroPhage Rank

MicroPhage Frequently Asked Questions (FAQ)

  • When was MicroPhage founded?

    MicroPhage was founded in 2002.

  • Where is MicroPhage's headquarters?

    MicroPhage's headquarters is located at 2400 Trade Centre Avenue, Longmont.

  • What is MicroPhage's latest funding round?

    MicroPhage's latest funding round is Series C.

  • How much did MicroPhage raise?

    MicroPhage raised a total of $36.65M.

  • Who are the investors of MicroPhage?

    Investors of MicroPhage include Alpine Angels, Qualifying Therapeutic Discovery Project, CTEK Venture Centers and Turner Biosystems.

  • Who are MicroPhage's competitors?

    Competitors of MicroPhage include Linkage Biosciences, Aviir, VitaPath Genetics, Aureon Laboratories, Crescent Diagnostics and 11 more.

Compare MicroPhage to Competitors

Helix Diagnostics

Helix Diagnostics LLC is pursuing development and commercialization of multiplexed DNA detection systems based on capillary electrophoresis.


3PrimiR is researching how mutations in micro RNA molecules can be used in cancer diagnostics.

Genera Biosystems

Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.

Crescent Diagnostics

Crescent Diagnostics develops Osentia, a commercially available diagnostic test to identify an individual's risk of developing osteoporosis.

Columbia BioSystems

Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.

Integrative Diagnostics

Integrative Diagnostics is a early cancer detection company founded by Leroy Hood.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.